Optilume DCB combines mechanical dilation with paclitaxel coating for effective urethral patency maintenance in recurrent anterior urethral strictures. ROBUST III trial shows significant improvements ...

The TRAVERSE trial is the largest randomized placebo-controlled study on testosterone therapy, impacting clinical perspectives on its risks and benefits. The study alleviates concerns about ...

MED3000 gel is FDA-cleared for over-the-counter use and improves erectile dysfunction outcomes for men and partners. A 12-week study across multiple countries showed significant improvements in SEP ...

A 400 mg BID dose of oral testosterone undecanoate significantly increases serum testosterone levels and improves symptoms in hypogonadal men. The study observed decreased sex hormone binding globulin ...

The "drain and retain" technique is safe for IPP revision surgeries without infection, avoiding morbidity from reservoir removal. Study across seven US centers showed similar infection rates for ...

FSD content is scarce in urology (1.4%) and OB/GYN (5.3%) residency programs, compared to MSD content in 50% of urology programs. No urology programs included FSD curricula, while 10 of 12 OB/GYN ...

Bel-sar demonstrated promising efficacy and safety in NMIBC, with complete clinical responses in most low-grade disease patients. The treatment induces tumor cell necrosis and pro-immunogenic cell ...

IPP from Boston Scientific and Coloplast significantly increased penile length and width post-surgery compared to preoperative measurements. The study involved 151 patients, with a mean age of 64.4 ...

“Nivolumab, combined with standard of care trimodality therapy, appears to be promising for the treatment of grade group 5 prostate cancer," says John Michael Bryant, MD.

Effective Xiaflex administration for Peyronie disease involves back-to-back injections and achieving an erection with the first injection of each series. Optimizing dosage, dilution, and incorporating ...

“Particularly [in] bladder cancer, there's 2 new drugs on the market that are exceptionally expensive, but they do provide benefit to patients,” says Geoffrey N. Sklar, MD, FACS. In this interview, ...

Five-fraction SBRT showed noninferiority to conventional radiotherapy in localized prostate cancer, with 95.8% of patients free from failure at five years. SBRT offers a shorter treatment duration, ...